Mayne Pharma Group Limited

1HFY22 Results Presentation
25 February 2022

Scott Richards, CEO
Peter Paltoglou, CFO

Disclaimer

The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company's audited Financial Statements and market disclosures. This material is not intended to be relied upon as advice to investors or potential investors.

Non-IFRS information

- Other than as indicated, the financial information contained in this document is directly extracted or calculated from the audited Financial Statements. Throughout this document some non-IFRS financial information is stated, excluding certain specified income and expenses. Results excluding such items are considered by the Directors to provide a meaningful basis for comparison from period to period.
- Earnings before interest, tax, depreciation and amortisation (EBITDA) – a non-IFRS term – is considered by Directors to be a meaningful measure of the operating earnings and performance of the Group and this information may be useful for investors.
- The non-IFRS financial information has not been audited by the Group's auditors.

Forward looking statements

- This presentation contains forward-looking statements that involve subjective judgement and analysis and are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to the Company. These forward looking statements use words such as 'potential', 'expect', 'anticipate', 'intend', 'plan' and 'may', and other words of similar meaning. No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including the Company). Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based. Given these uncertainties, readers are cautioned not to place undue reliance on such forward looking statements. Subject to the Company's continuous disclosure obligations at law and under the listing rules of the Australian Securities Exchange, the Company disclaims any obligation to update or revise any forward looking statements. The factors that may affect the Company's future performance include, among others: changes in economic conditions, changes in the legal and regulatory regimes in which the Company operates, litigation or government investigations, decisions by regulatory authorities, changes in behaviour of major customers, suppliers and competitors, interruptions to manufacturing or distribution, the success of research and development activities and research collaborations and the Company's ability to protect its intellectual property.

Other

- A glossary of industry terminology is contained in the Mayne Pharma Annual Report which can be accessed at maynepharma.com/investor-relations/results-reports and product descriptions are detailed at maynepharma.com/us-products and maynepharma.com/australian-products.
- ABSORICA®, ACTIKERALL®, ACZONE®, EFUDIX®, NEXTSTELLIS®, NUVARING®, PROTOPIC®, SOLARAZE®, SOLTAMOX®, TARGADOX® and TAZORAC® are trademarks of third parties.

Business and strategy update

Mayne Pharma overview

Company Overview

- Diversified pharma with novel brands, established brands, generics and contract services
- Transformational opportunity with NEXTSTELLIS® oral contraceptive
- Dermatology go-to-market approach attracting high quality pharma partners
- Highly valued US pure play CDMO business with double digit track record of growth
- $1.5b of assets across operations and $0.9b of tangible assets
- Multiple options for near term value creation

1HFY22 reported gross profit



>85%	of revenue in US
80%	of gross profit in growth categories
100+	marketed products
100+	contract service clients
2	internally owned manufacturing sites
15	export countries
900+	employees
1b	doses sold globally

Solid operating performance before NEXTSTELLIS® start-up investments

A$million[1]	1HFY22	1HFY21	Change 1HFY22 v 1HFY21	2HFY21	Change 1HFY22 v 2HFY21
Reported revenue	196.4	208.8	(6%)	192.0	2%
Reported gross profit[2]	89.3	96.9	(8%)	85.1	5%
Reported EBITDA	48.8	40.5	20%	25.6	91%
Reported net loss after tax	(50.4)	(181.3)	nm	(27.1)	nm
Underlying EBITDA[3]	23.7	38.5	(38%)	25.0	(5%)
Underlying EBITDA (excl. NEXTSTELLIS®)[4]	44.4	39.9	11%	32.8	35%

- Reported revenue excluding retail generics up 20% on 1HFY21
- Reported EBITDA affected by the non-cash NEXTSTELLIS® deferred consideration reassessment due to COVID and associated longer time period for physician and patient activation and higher cost of payer coverage and reimbursement
- Operating expenses (excluding NEXTSTELLIS®) down 12% or $8m on 1HFY21

1. Attributable to members. EBITDA excludes asset impairments.
2. Gross profit calculation includes A$7.5m depreciation in cost of sales
3. Adjustments to underlying EBITDA outlined on page 25
4. Excludes NEXTSTELLIS® direct contribution (gross profit less direct operating expenses)

Key operational highlights

- Metrics Contract Services revenue up 20% on pcp
- International revenue up 29% on pcp
- Dermatology revenue up 8% on pcp and up 67% on 2HFY21
- Solid growth in key performance metrics for NEXTSTELLIS® in 2QFY21 v 1QFY21 despite challenging COVID operating environment
- Signed five new supply agreements to launch up to 12 dermatology products
- Launched 8 dermatology products in the 1HFY22 with isotretinoin becoming the largest US product
- Launched 3 dermatology products in the 2HFY22 targeting addressable markets of US$450m including a top 3 dermatology product by IQVIA sales, generic ACZONE® (dapsone) and generic PROTOPIC® (tacrolimus)
- TGA approval of NEXTSTELLIS® oral contraceptive and Swissmedic approval of KAPANOL® for Opioid Substitution Therapy (OST)
- Renegotiated debt facilities to increase flexibility

Revised business segment structure to align with the current US products operating model

Segments

Branded Products Division



- Distributes medically differentiated specialty products in the US in the launch / growth phase
  - NEXTSTELLIS® (E4/DRSP) oral contraceptive
  - TOLSURA® (SUBA®-itraconazole) capsule

Portfolio Products Division



- Distributes established products in the US on a portfolio basis where alternate patient value propositions critical for future success
  - 20+ dermatology products
  - 20+ generic contraceptives
  - 40+ retail generics

Metrics Contract Services



- Provides contract pharmaceutical development, manufacturing and analytical services to third party customers globally
- Focused on niche and scientifically challenging areas with bias to high potency

International

- Develops, markets and distributes products globally
- Provides contract pharmaceutical development and manufacturing services globally
- Direct commercial presence in AU market

Business lines

Dermatology



- Marketed portfolio of brands and generics to largely non-retail customers

Retail generics



- Marketed portfolio of generics to largely retail channel

1. Reported gross profit

Five strategic priorities to drive shareholder value

1. Successfully commercialise NEXTSTELLIS® in the US

2. Drive growth of dermatology in established and alternate channels

3. Accelerate US Contract Service platform investing in broader capabilities and additional capacity

4. International growth through pipeline and capacity expansion

5. Corporate initiatives to accelerate transformation

NEXTSTELLIS® a novel oral contraceptive

- Contains estetrol (E4) – the first new estrogen introduced in the US in more than 50 years
  - E4 has a unique mechanism of action that offers potential advantages over other estrogens
- US commercial launch in June 2021 participating in the short acting combined hormonal contraceptive market valued at US$3.4b[1]
- TGA approval in November 2021, market valued at A$65m[1]
- 5 years of marketing exclusivity in US and Australia with potential further patent protection
- Experienced women's health commercial teams supporting launches
- Average time for patients on hormonal contraception is ~5-7 years

1. IQVIA MAT Sales

NEXTSTELLIS® launch momentum accelerating despite challenging COVID operating environment

HCP engagement

- >80,000 interactions with healthcare professionals (HCPs) including >9,000 education lunches and 25 speaker events
- Sales team reached >13,000 HCPs and 88% of top prescriber targets
- Amongst target HCPs NEXTSTELLIS® aided awareness is ~79% (versus 68% in August 2021) and unaided awareness is 31% (versus 15% in August 2021)
  - 88% of unaware target HCPs have an intent to prescribe NEXTSTELLIS® to an average of 18% of their patients after reading the product profile[1]

Market access

- Commercial coverage[2]: ~70% formulary access, ~55% unrestricted
- Medicaid: 96% formulary access, 37% unrestricted

Underlying demand since launch[3]

- >2,100 NEXTSTELLIS® writers or ~25% of target HCPs
- >21,000 TRx written
- >12,000 TRx dispensed and >20,000 cycles

1. NEXTSTELLIS® ATU study results February 2022
2. Health insurance coverage of patient lives
3. IQVIA and internal pharmacy partners

NEXTSTELLIS® key performance metrics



	1QFY22	2QFY22	Change 2QFY22 v 1QFY22
New writers	628	1,053	68%
NRx	1,076	3,774	251%
TRx	1,307	6,043	362%
Cycles	2,365	10,360	338%

Currently averaging ~100 new writers / week and >90% of 1QFY22 writers returned in the 2QFY22

Source: IQVIA and internal pharmacy partners

NEXTSTELLIS® prescriptions trending favourably despite the challenges of COVID and the more recent Omicron variant

NEXTSTELLIS® weekly performance metrics



NEXTSTELLIS® monthly performance metrics



Source: IQVIA weekly prescription data, 11 February 2022

Direct-to-consumer (DTC) campaign

- There is currently virtually no patient awareness of NEXTSTELLIS® among our target consumers
- >50% of women play an active role in choosing their contraceptive method
- >80% of the time brand requests by consumers are granted by HCPs
- Consumer campaign is targeted to launch when we achieve the following milestones
  - >75% awareness amongst target HCPs
  - >3,000 writers
  - ~60% unrestricted commercial coverage and >70% total coverage

Potential DTC channels



Affordable Care Act (ACA) compliance – potential significant tailwind for NEXTSTELLIS® in the mid term

- In January 2022 the US tri-agencies, Department of Labor, Health and Human Services and Treasury issued new guidance that supports women's access to FDA approved contraceptive products
- The guidance reminds insurers and Pharmacy Benefit Managers (PBMs) of their responsibility to fully comply with the requirements of the ACA and must provide coverage with no out-of-pocket costs to women for FDA approved and prescribed contraceptive products
- The new guidance takes effect for plan years beginning 2023

Potential impact on NEXTSTELLIS®

Greater patient access

Reduced patient out-of-pocket costs

Reduced abandonment rate

Dermatology go-to-market approach attracting high quality partners including some of the largest dermatology companies

Dermatology partnerships

SANDOZ A Novartis Division

torrent PHARMA

Encube

Chartwell PHARMACEUTICALS

UPSHER-SMITH

douglas

Cosette PHARMACEUTICALS

US dermatology marketed portfolio (number of products)



US dermatology direct contribution (US$m)



Mayne Pharma added five new dermatology partnerships and 12 products targeting markets with IQVIA sales of US$640m

Isotretinoin has become the largest US product by sales in the 1HFY22

ABSORICA® (isotretinoin) brand and generic market weekly prescriptions



- ABSORICA® (isotretinoin) product market has grown ~60% since our launch in September 2021
- Mayne Pharma has taken a significant share of the ABSORICA® (isotretinoin) product market which itself has grown, likely taking share from the broader isotretinoin market which has ~35,000 prescriptions / week

Source: IQVIA, weekly prescription data, brand and generic

Recent US generic product launches / pipeline

Product	Therapeutic area	Regulatory status	Target product market value[1] (US$m)	Number of Gx approved and marketed[2]	Launch status
Generic ABSORICA® (isotretinoin)	Acne	Approved	140	2	Launched Sep 2021
Generic TAZORAC® (tazarotene)	Acne	Approved	15	2	Launched Sep 2021
Generic TARGADOX® (doxycycline)	Acne	Approved	15	3	Launched Nov 2021
Generic PROTOPIC® (tacrolimus)	Atopic dermatitis	Approved	75	3	Launched Jan 2022
Topical	Acne	Approved	250	1	Launched Feb 2022
Generic ACZONE® (dapsone)	Acne	Approved	120	2	Launched Feb 2022
Topical	Acne	Approved	20	1	2HFY22
Topical	Acne	Filed	25	1	On approval
Generic NUVARING® Etonogestrel/ ethinyl estradiol	Contraception	Filed	630	2	On approval

1. IQVIA, MAT sales, December 2021. Includes brands and generic equivalents
2. Excludes authorised generics

US contract service business

- Metrics is one of a few high potent, small batch solid oral dose CDMOs with a single site for early-stage development through to commercialisation
- Track record of double-digit revenue and earnings growth
- 25+ years of history in novel oral solid dosage forms including high potent compounds
- Supports 12 of the top 20 global pharma companies[1]
- 68 projects across the pharmaceutical value chain
  - 62 novel molecules in development
  - 6 commercial products
- Significant flexibility to support expansion of commercial manufacturing activities
- CY21 operating profit of ~A$45m[2]

Metrics Contract Services historical revenue (US$m)



1. Fierce Pharma top 20 pharma companies by 2020 revenue
2. Direct contribution plus depreciation. Excludes corporate costs and internal manufacturing margin on PPD products

CDMO sector continues to exhibit strong M&A fundamentals

CDMO M&A volume (US$m)



CDMO trading multiples (EV / LTM EBITDA)



Recent CDMO M&A transactions

Date	Target	Acquirer	Price (US$m)	LTM EV/EBITDA multiple
Jul 21	Fertin	PMI	820	15x
May 21	Vectura	PMI	1,300	15x
Dec 20	Recipharm	EQT	4,000	17x
Aug 20	PCI Pharma	Kohlberg	N/A	20x
Aug 19	Cambrex	Pemira	2,500	16x
Nov 18	Avista	Cambrex	330	16x

Source: Broker reports

International segment delivering growth across all business lines

- Largest Australian owned full service solid dose plant manufacturing TGA and FDA registered pharmaceuticals
- 40+ years of expertise in drug delivery
- Outstanding compliance and quality track record
- Full service commercial engine for specialty pharmaceuticals in the Australian market
- Advanced pipeline of near-term new product launches in Australia and Europe
- Proven ‘concept to commercialisation’ track record
  - 70 product launches globally over the last decade

International historical revenue (A$m)



Select international pipeline for growth

Product	Country	Therapeutic area	Regulatory status	Target product market value[1] (A$m)	Potential launch timing
KAPANOL® (morphine sulphate)	Switzerland	Opioid substitution therapy	Approved	15	2HFY22
NEXTSTELLIS® (E4/DRSP)	Australia	Contraception	Approved	70	Mid CY22
KAPANOL® (morphine sulphate)	Austria / Germany	Opioid substitution therapy	Bioequivalence study	50	FY23
ACTIKERALL® (5FU / salicylic acid)	Australia	Actinic Keratosis	Approved	18	FY23
Generic EFUDIX® (5FU)	Australia	Actinic keratosis	Dossier preparation	18	FY23
Generic EFUDIX® (5FU)	UK	Actinic keratosis	Dossier preparation	11	FY23
FABIOR® (tazarotene)	Australia	Acne	Filed	11	FY23
LEXETTE® (halobetasol)	Australia	Psoriasis	Dossier preparation	43	FY24

1. IQVIA MAT sales December 2020

Business development initiatives to accelerate transformation

Women's Health

- Broaden women's health portfolio in areas of unmet need
- Seek out highly complementary products with strong growth potential that can be marketed through existing women's health sales team to leverage existing commercial infrastructure and strengthen position in the market

Dermatology

- Expand dermatology portfolio through partnering and exploiting a unique go-to-market approach
- Addition of complementary brand and generic products to leverage established commercial capabilities

Board transformation agenda

Board renewal

- Board refresh with the addition of new directors with deep pharmaceutical experience
  - Frank Condella, appointed to the Board in 2018, was appointed Chair effective 30 September 2021
  - Carolyn Myers, PhD effective 4 October 2021
  - Kathryn MacFarlane, PharmD effective 1 February 2022
- Retirement of Roger Corbett, Bruce Mathieson and Nancy Dolan

Corporate strategy

- Strategy is to reposition portfolio away from retail generics into more sustainable categories in women's health, dermatology and contract services and participate in the disintermediation of the US pharma value chain

Undervalued assets

- Proactively exploring options to unlock the value of Mayne Pharma's businesses through active management of the corporate portfolio for the benefit of shareholders
- Focused on creating a leaner, more focused operating model

Financial results

Adjustments to earnings[1] – 1HFY22

A$million	EBITDA adjustments 1HFY22	1HFY21	Comments
Reported	48.8	40.5	
Earn-out revaluation	(32.1)	(5.6)	Non-cash credit arising from a decrease in the fair value of earn-out liabilities of which $30.5m relates to NEXTSTELLIS®
Sale of land	(3.7)	-	Gain on the sale of surplus land in Salisbury, SA
Discontinued products	5.6	-	Relate largely to exit costs for discontinued products
Restructuring	3.4	1.9	Organisational transformation to further simplify operating model. Targeting US$4m+ of annualised benefits in FY23
Litigation	1.6	1.4	Legal costs associated with generic pricing litigation, and DOJ investigation seeking information relating to claims submitted to federal health care programs
Inhibitor Therapeutics	0.1	0.3	Mayne Pharma's share of Inhibitor Therapeutics, Inc. (INTI) losses
Total adjustments	(25.1)	(2.0)	
Underlying	**23.7**	**38.5**	
NEXTSTELLIS®	20.7	1.4	NEXTSTELLIS® gross margin less direct operating expenses
Underling (excluding NEXTSTELLIS®)	**44.4**	**39.9**	

1. Attributable to members

Reported to underlying earnings attributable to members

A$million	Reported 1HFY22	Earn-out reassessment	Restructuring	Discontinued products	Impairment	Litigation	Sale of land	INTI	Underlying 1HFY22	NEXTSTELLIS	Underlying excluding NEXTSTELLIS
Revenue	**196.4**			**(0.8)**					**195.6**	**1.5**	**194.1**
Gross profit	89.3			5.6					94.9	0.8	94.1
Gross profit %	*45%*								*49%*	*53%*	*48%*
EBITDA	**48.8**	**(32.1)**	**3.4**	**5.6**		**1.6**	**(3.7)**	**0.1**	**23.7**	**(20.7)**	**44.4**
Depreciation / Amortisation	(41.5)							0.2	(41.3)	(13.1)	(28.4)
Impairments	(56.0)				56.0				-	-	-
PBIT	**(48.7)**	**(32.1)**	**3.4**	**5.6**	**56.0**	**1.6**	**(3.7)**	**0.3**	**(17.6)**	**(33.8)**	**16.2**
Net finance cash costs	(4.4)								(4.4)		(4.4)
Finance non cash costs – e.g. discount unwind	(10.4)								(10.4)	(7.8)	(2.6)
PBT	**(63.5)**	**(32.1)**	**3.4**	**5.6**	**56.0**	**1.6**	**(3.7)**	**0.3**	**(32.4)**	**(41.6)**	**9.2**

Metrics Contract Services (MCS or Metrics)

- In USD terms, Metrics revenue was US$33.7m, up 21% on pcp driven largely by new commercial manufacturing revenue
- Significant expansion of margins reflecting strong cost control
- Commercial manufacturing revenue now represents 27% of MCS revenue up from 14% in the pcp
- Formulation development revenues grew 10% in USD terms benefiting from 5 new CDMO customers and 23 new projects in 1HFY22
- Positive business outlook with the pipeline of committed business[2] at its highest level ever

A$million	1HFY22	1HFY21	Change 1HFY22 v 1HFY21
Reported revenue	46.0	38.5	20%
Gross Profit	24.7	18.5	33%
Gross Profit %	54%	48%	
Direct operating expense[1]	2.6	2.4	6%
Direct contribution	22.1	16.1	37%

1. Direct marketing costs
2. Committed business pipeline is the next six months of signed purchase orders / statements of work

International or MPI

- International benefited from growth in all business lines
  - CDMO revenue up 39% on pcp
  - Australian product revenue up 15% on pcp
- 21 active formulation development projects, up from 9 in the pcp
- CDMO also benefited from growing sales of KAPANOL® (morphine) in Canada and Switzerland and greater ASTRIX® (aspirin) sales in Korea
- Australian products benefited from the launch of SOLARAZE® (diclofenac) and a PBS price increase on erythromycin
- Received TGA approval for NEXTSTELLIS® (E4/DRSP) in Australia and KAPANOL® received Swissmedic approval for Opioid Substitution Therapy (OST)

A$million	1HFY22	1HFY21	Change 1HFY22 v 1HFY21
Reported revenue	27.6	21.3	29%
Gross Profit	8.8	6.9	27%
Gross Profit %	32%	32%	
Direct operating expense[1]	4.7	5.3	(12%)
Direct contribution	4.1	1.6	155%

1. Direct marketing costs and general administration expenses including finance, HR and IT

Branded Products (BPD)

- NEXTSTELLIS® revenues were US$1.1m and operating expenses were US$15.7m
- TOLSURA® (itraconazole) and SOLTAMOX® (tamoxifen) revenues were US$1.3m and US$0.7m
- Focused on obtaining optimal market access
- Strategically investing to maximise ROI

A$million	1HFY22	1HFY21	Change 1HFY22 v 1HFY21
Reported revenue	4.2	1.5	185%
Gross Profit	3.3	1.4	142%
Gross Profit %	78%	92%	
Direct operating expense[1]	25.7	4.6	460%
Direct contribution	(22.5)	(3.2)	Nm

1. Direct marketing costs

Portfolio Products (PPD)

- Dermatology revenue up 8% on pcp and direct contribution up 32% on pcp
  - Generic ABSORICA® (isotretinoin) became largest US product by sales
  - Continued commercial discipline across established portfolio with improving dermatology profitability
- Retail generics impacted by ongoing pricing pressure and additional competition across the portfolio
  - Rationalisation of portfolio leading to discontinuing unprofitable generic products
- 1HFY22 PPD revenue was down 2% and direct contribution was up 4% on 2HFY21

A$million	1HFY22	1HFY21	Change 1HFY22 v 1HFY21	2HFY21	Change 1HFY21 v 2HFY21
- Dermatology revenue	41.7	38.7	8%	24.9	67%
- Retail generic revenue	76.9	108.8	(29%)	95.9	(20%)
Reported revenue	118.6	147.6	(20%)	120.8	(2%)
Gross Profit	52.6	70.1	(25%)	50.4	4%
Gross Profit %	44%	47%		42%	
Direct operating expense[1]	15.8	18.7	(15%)	15.1	5%
Direct contribution	36.7	51.4	(29%)	35.3	4%

1. Direct marketing costs

Continued optimisation of the cost base (excluding NEXTSTELLIS®)

Operating expenses[1]

A$million	1HFY22	1HFY21	Change $	Change %
Marketing & distribution	27.5	28.8	(1.3)	(4%)
Share based payments	3.1	3.8	(0.7)	(18%)
All other admin[2]	22.1	25.3	(3.1)	(12%)
Total opex expenses	**52.7**	**57.8**	**(5.1)**	**(9%)**

- Operating expenses down $5m on pcp benefiting from strong cost control

R&D spend[1]

A$million	1HFY22	1HFY21	Change $	Change %
R&D expensed	7.4	10.3	(2.9)	(28%)
R&D capitalised	0.8	2.6	(1.8)	(68%)
Gross R&D	**8.2**	**12.9**	**(4.7)**	**(36%)**
R&D capitalisation rate	*10%*	*20%*		
R&D as % revenue	*4%*	*6%*		

- Gross R&D spend down $5m as the company continues to streamline any direct investment and move to a more partnership based model to risk share

1. 100% consolidated. Depreciation included in R&D expense (A$0.5m), marketing & distribution (A$0.4m) and all other admin (A$1.4m)
2. Refer to 'All other administration and other expenses' in note 3 of the Financial Statements. Excludes non-cash items

Consolidated balance sheet position

A$million	As at 31 Dec 21	As at 30 Jun 21	Change $m
Cash	114.7	98.0	16.7
Inventory	111.9	102.5	9.4
Receivables	206.7	183.3	23.4
PP&E	212.9	212.5	0.4
Intangibles & goodwill	571.8	636.1	(64.4)
Income tax receivable	20.9	20.3	0.6
Right of use assets	8.0	9.1	(1.1)
Other assets	221.1	201.4	19.7
Total assets	**1,467.9**	**1,463.2**	**4.7**
Payables	130.8	113.7	17.0
Borrowings	387.3	346.8	40.5
Other financial liabilities	171.9	197.9	(26.0)
Other liabilities	29.0	33.1	(4.1)
Equity	**748.9**	**771.6**	**(22.7)**
Equity (attributable to members)	**745.8**	**768.4**	**(22.6)**
AUD:USD FX rate	0.726	0.751	
Net debt	**272.6**	**248.8**	**23.8**

Consolidated cash flow – EBITDA to cash reconciliation

	Half year ending		Change
A$million	**31 Dec 21**	**31 Dec 20**	
Reported EBITDA attributable to members[1]	48.8	40.5	8.3
Minority share of INTI EBITDA	(0.1)	(0.2)	0.1
Consolidated EBITDA (100% INTI)	48.7	40.3	8.4
Share based payments (non-cash)	3.1	3.8	(0.7)
Movement in earn-outs (non-cash)	(32.1)	(5.7)	(26.4)
Provisions (non-cash)	2.3	4.3	(2.0)
Other	(3.1)	(0.8)	(2.5)
Operating Cash flow Before WC and tax	**18.8**	**41.9**	(23.2)
WC movements	(18.3)	(9.6)	(8.7)
Net tax (paid) / received	(0.1)	13.9	(13.9)
Net operating cash flow	**0.4**	**46.2**	(45.8)
Capitalised R&D	(0.8)	(2.6)	1.8
Acquisitions / sale of land	5.2	(2.0)	7.2
Capex	(4.8)	(6.4)	1.6
Earn-out & deferred settlement payments	(12.2)	(7.7)	(4.5)
Free cash flow	**(12.2)**	**27.5**	(39.7)
Net proceeds borrowings & shares	26.4	(20.8)	47.2
Net cash flow	**14.2**	**6.7**	7.5

- Cash flow working capital movements based on average AUD/USD exchange rate for the period whereas the December balance sheet balances based on closing rates
- Increased working capital reflects the investment in inventory and receivables to support the launch of NEXTSTELLIS® and the new dermatology products

1. Reported EBITDA in Director's Report is attributable to members. Cash flow in the Financial Statements is on a consolidated basis and includes 100% of INTI

Capital structure

- Dual currency debt facility
  - US$200m, 5 year revolving facility, matures November 2023
  - US$100m, 4 year bullet facility, matures November 2024
  - US$65m, 364 days receivables financing facility (non-recourse facility)
  - A$10m, 2 year working capital facility, matures November 2023
- Net debt under syndicated debt facility is $225m and bank EBITDA is $71m for the last 12 months ending 31 December 2021

Key financial metrics

A$million	As at 31 Dec 21	As at 30 Jun 21	Change $
Syndicated facility	330.6	298.8	31.8
Deferred borrowing costs	(3.9)	(4.0)	0.1
Receivables financing	51.8	42.2	9.6
Lease liabilities	8.8	9.9	(1.1)
Borrowings	387.3	346.8	40.4
Cash	114.7	98.0	16.7
Net debt	272.6	248.8	23.8
Net debt (under debt facility terms)[1]	**224.7**	**210.8**	**13.9**
Leverage ratio: Net debt / EBITDA Covenant <4.25x	3.2x	2.6x	
Interest cover ratio: EBITDA / interest Covenant >3x	7.7x	7.9x	
Shareholder's funds Covenant > A$600m	A$754m	A$776m	

1. Net debt defined under syndicated debt facility includes lease liabilities but excludes deferred borrowing costs and any drawn funds under receivables financing facility. EBITDA excludes non cash items such as share based payments expense, earn-out revaluation and certain restructuring costs.

Historical reported segment information

Reported results (A$m)	1HFY22	2HFY21	1HFY21	FY21
Revenue				
- Dermatology	41.7	25.0	38.8	63.8
- Retail generics	76.9	95.8	108.8	204.6
Portfolio Products	118.6	120.8	147.6	268.4
Branded Products	4.2	6.1	1.5	7.5
Metrics Contract Services	46.0	43.6	38.5	82.1
International	27.6	21.5	21.3	42.8
Total	196.4	191.9	208.8	400.8

	1HFY22	2HFY21	1HFY21	FY21
Gross profit				
- Dermatology	33.4	20.2	31.9	52.2
- Retail generics	19.2	30.1	38.1	68.2
Portfolio Products	52.6	50.4	70.1	120.4
Branded Products	3.3	5.1	1.4	6.5
Metrics Contract Services	24.7	23.3	18.5	41.8
International	8.8	6.3	6.9	13.2
Total	89.3	85.1	96.9	181.9

Operating expenses				
- Dermatology	11.8	12.5	15.5	28.0
- Retail generics	3.4	2.7	3.2	5.9
- Other	0.7			
Portfolio Products	15.8	15.1	18.7	33.9
Branded Products	25.7	14.9	4.6	19.5
Metrics Contract Services	2.6	2.3	2.4	4.7
International	4.7	4.8	5.3	10.1
Total	48.8	37.2	31.0	68.2

Direct Contribution				
- Dermatology	21.6	7.8	16.4	24.2
- Retail generics	15.8	27.4	35.0	62.4
- Other	- 0.7			
Portfolio Products	36.7	35.2	51.4	86.6
Branded Products	- 22.5	- 9.8	- 3.2	- 13.0
Metrics Contract Services	22.1	21.0	16.1	37.1
International	4.1	1.5	1.6	3.1
Total	40.5	47.9	65.8	113.7